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doi:10.1Objective: Transcatheter aortic valve implantation is considered an alternative for patients at high risk for
conventional surgery. The Direct Flow Medical aortic valve (Direct Flow Medical, Inc, Santa Rosa, Calif) is
a nonmetallic tissue valve prosthesis intended to treat patients with severe aortic stenosis at high risk for surgery.
Methods: Thirty-one patients at high surgical risk were enrolled in the trial (logistic EuroSCORE 28%  7%,
Society of Thoracic Surgeons score 23% 9%). Twenty-two patients underwent successful retrograde transcath-
eter aortic valve implantation, and 9 patients did not undergo implantation owing to excessive calcifications or ac-
cess issues. Mean preinterventional gradient and effective orifice area were 49 14 mm Hg and 0.54 0.16 cm2,
respectively, and 71% of patients were in New York Heart Association functional class III.
Results: Mean postprocedural gradient was 14.9  5.5 mm Hg with an effective orifice area of 1.4  0.31 cm2.
Two patients were converted to surgery and 2 patients died after implantation: 1 of myocardial infarction and 1 of
congestive heart failure. One patient had a stroke 2 days after the procedure and 3 patients required a pacemaker.
At 6 months the mean aortic valve gradient and effective orifice area were 19.8 mm Hg and 1.30 cm2, respectively.
The majority of patients had no paravalvular leak (58%) and 42% had grade 1/4 paravalvular leak; 69% were in
New York Heart Association functional class I and 25% were in class II. The 3- and 6-month survivals were
87.1% and 80.6%, respectively (4/6 deaths in 31 patients).
Conclusions: Transcatheter aortic valve implantation using the study valve appears safe and results are promising
at 6 months. Severe leaflet and left ventricular outflow tract calcification affects procedural outcome; therefore,
careful patient selection is crucial. (J Thorac Cardiovasc Surg 2010;140:897-903)T
/B
STranscatheter aortic valve implantation (TAVI) has become
a considerable alternative for patients at high risk for open
surgical treatment. It offers a treatment option for patients
whose condition is considered inoperable owing to exten-
sive calcifications of the ascending aorta or in patients of
advanced age with significant comorbidities. The Euro Heart
Survey, a European registry of 5000 patients in 25 countries,
revealed that 31.8% of patients with symptomatic aortic
stenosis did not undergo surgical aortic valve replacement
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EThere are currently two commercially available TAVI valve
types in Europe (Edwards SAPIEN; Edwards Lifesciences,
Irvine, Calif; Medtronic CoreValve Revalving System;
Medtronic, Inc, Minneapolis, Minn). Both are based on stent
technology and offer only limited possibilities of reposition-
ing and no options for retrieval during implantation. Subop-
timal placement of the devices may lead to urgent surgical
intervention at increased risk.
The Direct Flow Medical aortic valve (Direct Flow Med-
ical, Inc, Santa Rosa, Calif) is the first transfemorally deliv-
ered aortic valve prosthesis that is not based on a metallic
stent frame technology. It allows for retrieval, repositioning,
or sizing exchange before permanent implantation. Rapid
pacing is repeatedly used during standard balloon valvulo-
plasty of the native aortic valve; it is not required for posi-
tioning or deploying the prosthesis. The initial results of
this feasibility study of the Direct Flow Medical aortic valve
were positive, demonstrating safety during the implantation
procedure, with significant reduction in mean transvalvular
pressure gradients and an increase in aortic valve area after
successful implant.2
Herein, we report the immediate postprocedure and
6-month follow-up data from the nonrandomized, prospec-
tive clinical trial of 31 enrolled patients eligible forrdiovascular Surgery c Volume 140, Number 4 897
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AR ¼ aortic regurgitation
CEC ¼ clinical events committee
EuroSCORE ¼ European System for Cardiac
Operative Risk Evaluation
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The Direct Flow Medical aortic valve is designed as a trileaflet bovine
pericardial tissue valve (Figure 1). It is attached to an inflatable framework
with a slightly tapered, conformable polyester fabric cuff.3,4 The upper and
lower margins of the cuff consist of two independently inflatable rings
connected by a tubular system. The upper aortic ring is connected to three
evenly distributed detachable positioning and fill lumina (PFLs) that are
used to inflate and deflate the valve, as well as to accurately position in
the native annulus. The folded valve is loaded into a 22F sheath at the
end of a 15F delivery catheter with an olive-shaped tip designed to seal
the distal end of the delivery sheath and to facilitate an atraumatic passage
through the aorta. Two of the PFLs enable inflation and deflation of both the
aortic and the ventricular rings on the cuff, and all three allow for correct
positioning of the valve in the native annulus by pushing and pulling at
the proximal ends. The loaded delivery system is advanced over a guide
wire placed transvalvularly in the left ventricle. A basket-like nitinol recov-
ery system can be introduced into the delivery sheath to retrieve the valve if
required (Figure 2).
Patients
Between September 2007 and August 2008, 31 patients (15 men and 16
women; mean age 82  4 years) were enrolled at two facilities in Germany
(25 patients at University Cardiovascular and University Heart Center,
Hamburg, and 6 patients at HELIOS Heart Center, Siegburg). All patients
had severe aortic valve stenosis and were at high risk for open cardiac surgery,
and the vast majority of patients were symptomatic (97%). Relevant comor-
bidities of all patients are listed in Table 1. Surgical risk was evaluated by
a logistic European System for Cardiac Operative Risk Evaluation (Euro-
SCORE)5 and considered high by consensus of two independent experienced
cardiac surgeons who were not members of the study group. Inclusion criteria
were an aortic valve area of 0.8 cm2 or less, a mean transvalvular pressure
gradient of 35 mm Hg or more, an aortic annulus diameter between 19 and
23 mm, age of 70 years or more, and a logistic EuroSCORE of 20% or
more. Patients with a life expectancy of 1 year or less, serum creatinine of
2.0 mg/dL or more, prior valve surgery, endocarditis during the past
18 months, recent myocardial infarction (<30 days), stroke during the prior
6 months, or clinically significant mitral regurgitation (>grade 2þ/4) were ex-
cluded from the trial. Computed tomographic scans of the aorta and the fem-898 The Journal of Thoracic and Cardiovascular Surgoral and iliac vessels were performed and reconstructed in 3 dimensions to
evaluate patients for iliofemoral calcification, tortuosity, and access vessel
diameter (femoral artery minimum inner diameter of 7.5 mm). Mean logistic
EuroSCORE for the study patients was 28% 7%. The majority (71%) of
patients were in New York Heart Association (NYHA) functional class III,
26% of patients were in NYHA class II, and 3% were in NYHA class I
(Figure 3). Preinterventional transthoracic echocardiography (TTE) revealed
a mean aortic transvalvular gradient of 49  14 mm Hg and an effective
orifice area of 0.5 0.16 cm2 (Figure 4). Mean left ventricular ejection frac-
tion was 53%  15%. The study was approved by the German National
Committee and locally by the Ethics Committees of the Hamburg and Sieg-
burg Boards of Physicians, and all patients provided written informed consent
in accordance with the principles of the Declaration of Helsinki.Valve Implantation
All procedures were performed using general anesthesia in a hybrid
suite equipped for cardiologic interventions and cardiac operations. Trans-
esophageal echocardiography (TEE) was performed throughout the proce-
dure. All patients received acetylsalicylic acid (at least 100 mg daily) and
clopidogrel (300 mg loading dose, if patient was not currently receiving
clopidogrel) and then 75 mg daily 3 to 5 days before the procedure. Ace-
tylsalicylic acid therapy was continued for life and an antiplatelet regimen
was continued for at least 6 months after the procedure in all patients as
per the study protocol. After surgical dissection of the right or left femoral
artery, a weight-dependent bolus of 5000 to 10,000 units of heparin was
administered intravenously to achieve an activated clotting time of more
than 300 seconds. A pacemaker lead was placed in the right ventricle
through the right jugular vein and tested for proper performance. A pigtail
catheter was placed in the ascending aorta over a 6F sheath through the
contralateral femoral artery. The 22F introducer sheath was placed care-
fully in the dissected femoral artery under fluoroscopic control. Balloon
valvuloplasty was then performed with standard technique using rapid
pacing (180–220 beats/min) and valvuloplasty balloons ranging from 18
mm to 28 mm. Valvuloplasty was repeated until sufficient mobilization
of the native leaflets was achieved and the mean pressure gradient drop-
ped to 30 mm Hg or less. In the first half of the study a median of 7 in-
flations occurred, whereas in the second half of the study a median of 5
inflations resulted in a typical gradient of 30 mm Hg or less. A stiff
wire was placed in the left ventricle through the stenotic native valve be-
fore the loaded delivery catheter was introduced and carefully advanced
over the wire through the aorta. Once the device tracked through the aorta
and crossed the native valve, the delivery catheter was pulled back and the
deflated valve was unfolded in the left ventricle. After inflation of the ven-
tricular ring with 50:50 saline/contrast, the pericardial leaflets were imme-
diately competent and no additional rapid pacing was required. Adjusting
the PFLs allowed the lower (ventricular) ring to be positioned and aligned
in the native aortic annulus and the left ventricular outflow tract under
fluoroscopic and echocardiographic visualization. Then, the upper (aortic)
ring and the transverse tubes were inflated. This pushed the calcified na-
tive valve against the aortic root, thereby covering the native annulus. The
prosthetic valve was then tested for correct subcoronary position, proper
function and paravalvular leakage by TEE, fluoroscopy, and aortography.
If necessary, repositioning was performed after partial deflation, or if
needed the valve was completely removed and exchanged for a valve
of a different size. When correct position and function were achieved,
the saline/contrast mix was exchanged with a fluid polymer under con-
stant pressure of 8 to 10 atmospheres. The full saline/polymer exchange
occurred in a maximum of 10 minutes with the polymer firmly gelled
in another 90 minutes and fully cured within 24 hours. During the
exchange of the inflation media, the valve remained fully pressurized,
competent, and in position. The PFLs were then detached from the upper
ring and the delivery system removed. TEE and aortography were per-
formed to reconfirm coronary flow, paravalvular and central leakages,
transvalvular pressure gradient, and valve opening area. The femoralery c October 2010
FIGURE 1. Expanded Direct Flow Medical aortic valve connected to
positioning-and-fill lumina (PFLs).
TABLE 1. List and percentage of comorbidities of all patients
(intention-to-treat group)
Baseline characteristics % (n)
Abdominal surgery 29% (9)
Angina (stable) 16% (5)
Arrhythmia (asymptomatic) 39% (12)
Arrhythmia (symptomatic) 7% (2)
CABG (prior) 10% (3)
Cancer 42% (13)
Carotid artery disease 32% (10)
CHF (drug compensated) 39% (12)
CHF (symptomatic) 35% (11)
Chronic renal insufficiency 39% (12)
COPD 19% (6)




MI<6 mo 3% (1)
MI>6 mo 7% (2)
Peripheral artery disease 26% (8)
Prior PTCA 26% (8)
TIA 3% (1)
CABG, Coronary artery bypass grafting; CHF, congestive heart failure; COPD,
chronic obstructive pulmonary disease; CVA, cerebrovascular accident; MI, myocar-
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Sartery was closed after removal of the introducer sheath by tying the
purse-string sutures. Then the access site was closed surgically.
Follow-up
Patients underwent follow-up examinations including transthoracic
echocardiography (TTE) and NYHA functional class status after 1 day,
30 days, and 6 months. To make accurate baseline and follow-up compar-
isons, we have reported all echocardiographic data from TTE.
Statistics
Continuous variables are presented by mean and interquartile range
(IQR). Categorical variables are presented as counts and percentages.
Ninety-five percent confidence intervals were calculated on the basis of
the binomial distribution. Changes in continuous variables between baseline
and at 30 days and 6 months were assessed by the Wilcoxon signed rank
test. Comparisons between categorical variables were performed with the
continuity-corrected c2 test. These analyses used StatView 4.5 software
package (Abacus Concepts, Inc, Berkeley, Calif). All statistical calculations
were completed by an independent statistician. Authors had full access to
the complete data set and take responsibility for its integrity. All authors
have read and agreed to the manuscript as written.
RESULTS
Procedure to Hospital Discharge
Thirty-one patients were enrolled in the study on provid-
ing written informed consent before study-related diagnos-
tic imaging. Diagnostic imaging was performed with TTE
and 3-dimensional reconstruction of computed tomographic
scans of the access site and native aortic valve.FIGURE 2. Direct Flow Medical aortic valve enfolded in nitinol retrieval
basket.
The Journal of Thoracic and CaAll 31 patients were included in the intention-to-treat pop-
ulation. Figure 5 demonstrates the study flow of these
patients.
In 9 patients, transfemoral implantation of the valve was
not attempted or was not successful owing to the following
reasons:
 Excessive tortuosity and calcification of the native vas-
culature prevented successful insertion of the catheter
(n ¼ 2). One of the patients was successfully treated
with a 23-mm transapical Edwards SAPIEN prosthesis0%
NYHA Class I 3% 73% 69%
NYHA Class II 26% 20% 25%
NYHA Class III 71% 7% 6%
NYHA Class IV 0% 0% 0%
Baseline 30 days 6 months
FIGURE 3. New York Heart Association (NYHA) functional class before
and after valve implantation.
rdiovascular Surgery c Volume 140, Number 4 899
E
FIGURE 4. Mean transvalvular gradients (mm Hg) and mean effective orifice area (cm2) (P¼ .001and P¼ .002 before and after intervention, respectively).
AV, Aortic valve; EOA, effective orifice area.





S4 months after the initial procedure. The other patient
refused to undergo another procedure and was treated
medically during the follow-up period.
 Functionally bicuspid aortic valves prevented success-
ful ballooning of the native valve (n ¼ 2). In the first
patient, an attempt to implant a 23-mm device was un-
successful owing to improper expansion of the cuff.
The valve was successfully retrieved by the retrieval
basket system and the patient underwent successful
surgical aortic valve replacement 9 days later. In the
second patient, no device implantation was attempted.
Balloon valvuloplasty reduced the maximum aortic
pressure gradient from 102 to 35 mm Hg. The patient
was treated medically during the follow-up period of
6 months.
 Excessive calcification of the left ventricular outflow
tract impeded correct positioning of the lower ring
(n ¼ 1). This valve was successfully retrieved. The
patient could only be treated medically during the
follow-up period of 6 months.
 The annular diameter of the native valve was in excess
of 27 mm and was underestimated in the preoperative
computed tomographic scans. Implantation was not
possible (n¼ 1). This valve was successfully retrieved.
The patient was given medical therapy and followed
up for 1 month.
 Excessive calcification of the native leaflets hindered
valve deployment (n¼ 1). This valve was successfully
retrieved. The patient was also given medical therapy
and followed up for 1 month.
 Septal dissection occurred during valvuloplasty
(n ¼ 1). The patient died during the procedure before
catheter insertion. This death was adjudicated by0 The Journal of Thoracic and Cardiovascular Surga Clinical Events Committee (CEC) to be procedure-
related but not device-related.
 Pulmonary embolism occurred during the procedure
(n ¼ 1). The valve was successfully retrieved, but
the patient never recovered. This death was also adju-
dicated by a CEC to be procedure-related but not
device-related.
Those patients who did not receive the study valve were
followed up out to 30 days after the procedure and then
were considered to have completed the study. Six months
of data are available for 7 of 9 patients.
Twenty-two patients underwent implantation of the
Direct Flow Medical aortic valve (procedural success rate
71%). Procedure time varied between the first 12 and the
last 10 cases with respect to the learning curve. In the first
12 patients, mean procedure time was 192.8 minutes with
an IQR of 87.5 minutes (start of cutdown to final closure).
In the last 10 patients, mean procedure time was 174.7 min-
utes with an IQR of 117.0 (start of cutdown to final closure).
Mean fluoroscopy time was 39.2 minutes. Transvalvular
pressure gradients decreased from a mean of 50.2 mm Hg
(IQR 40.5–59 mm Hg) preoperatively to 14.9 mm Hg
(IQR 10.5–18.5 mm Hg) postoperatively (P< .0001). The
effective orifice area was increased from a mean of 0.55
cm2 (IQR 0.43–0.64 cm2) to 1.39 cm2 (IQR 1.21–1.7 cm2)
over the same time period (P<.0001). Paravalvular leakage
and aortic regurgitation (AR) were limited with a maximum
AR score of AR grade 1þ/4, with the exception of 1 patient
who died on the day of the procedure of congestive heart
failure (AR grade 2þ/4).
Four major adverse cardiovascular and cerebral events
(MACCEs) occurred in-hospital after successful valveery c October 2010
FIGURE 5. Diagram illustrating study flow of intention-to-treat patient population. ITT, Intention to treat; LVOT, left ventricular outflow tract;CoD, cause of
death; MI, myocardial infarction; CHF, congestive heart failure; AR, aortic regurgitation; EF, ejection fraction; Resp, respiratory.




Simplantation (MACCE rate 12.9%; 4/31 patients): 1 patient
with a history of chronic atrial fibrillation had a postproce-
dural stroke with dysarthria and weakness of the right arm
at day 1, another patient died on day 2 of inferior wall myo-
cardial infarction, and 2 patients showed an increase in trans-
valvular gradients postoperatively and underwent surgical
aortic valve replacement at day 2 and day 8, respectively.
In those patients converted to surgery, gradient increase
was attributed to an oversized valve with consecutive distor-
tion of the upper ring in 1 patient and incorrect positioning of
the properly sized valve in the second patient.
Other significant events included the following*: obstruc-
tion of the left coronary artery by a plaque shift from a highly
calcified aortic root, which occurred after valve deployment.
Stenting of the left main stem was performed immediately
with good procedural result. Further, atrioventricular con-* For the purpose of a thorough review, events are listed individually rather than by
patient. One patient may account for more than one event discussed in this article.
The Journal of Thoracic and Caduction blockage was seen in 3 patients and led to uncompli-
cated postinterventional pacemaker implantation. Of these
3 patients, 2 continue to require long-term pacing and the
third did not require pacing after discharge.
In total, 18 patients were discharged from hospital with
permanent implants. Of this population, 17 patients had an
uneventful course and were discharged after a mean of
7 days (IQR 6–7 days). The patient who had the stroke
was not immediately discharged but rather was sent to
a rehabilitation unit for further care.Thirty-Day Follow-up
Clinical follow-up was completed after 30 days on the dis-
charged population. Survival at 30 days for the 18 patients
who were discharged from the hospital with permanent
implants was 100% and overall mortality of the intention-
to-treat population at this time point was 12.9% (4 deaths
in 31 patients). TTE revealed an increase in transvalvular
gradient that was not clinically significant (mean gradientrdiovascular Surgery c Volume 140, Number 4 901




S19.4 mm Hg vs 14.9 mm Hg; P ¼ .007), whereas effective
orifice area did not change significantly after the procedure
(1.46 cm2 vs 1.39 cm2; P ¼ .8) (Figure 4). Paravalvular
and intravalvular leaks were identical to the postprocedural
examination (no leak in 11 patients; minor paravalvular
leaks [AR grade 1/4] in 5 patients; minor central leaks
[AR grade 1/4] in 2 patients). NYHA functional class im-
proved significantly 30 days after valve implantation. The
majority of patients (73%) were in NYHA functional class
I, 20% were in class II, and 7% in class III (P ¼ .015)
(Figure 3).
Six-Month Follow-up
Six-month survival for the 18 patients who were dis-
charged from the hospital with permanent implants was
89% (2 deaths in 18 patients). Overall 6-month survival of
the intention-to-treat population was 80.6% (6 deaths in
31 patients).
One patient died during a routine hospital stay after spinal
surgery as a result of acute respiratory failure after pneumo-
nia 193 days after implantation. This death was adjudicated
by the CEC as not related to the procedure or the study valve.
A second patient died of an unknown cause while in rehabil-
itation 142 days after implantation. This death was consid-
ered by the CEC as possibly of cardiac origin although the
final cause of death remains unclear.
TTE at 6 months revealed stable transvalvular gradients
(mean gradient 19.8 mm Hg vs 19.4 mm Hg at 30 days)
and an insignificant decrease in effective orifice areas
(1.30 cm2 vs 1.46 cm2 at 30 days) (Figure 4). NYHA func-
tional class remained improved at 6 months with 69% of pa-
tients in class I, 25% in class II, and 6% in class III
(Figure 3). The majority of patients did not show any para-
valvular leaks (68.8%, 11/16 patients). Only minor
paravalvular leaks (AR grade 1/4) were found in 4 patients
and a minor central leak (AR grade 2/4) in 1 patient.
DISCUSSION
Symptomatic aortic stenosis carries a poor prognosis. Sur-
gical treatment by conventional aortic valve replacement
using cardiopulmonary bypass and cardioplegic arrest has
been established as the gold standard therapy with defined
indications, low operative risk, and excellent long-term out-
come. However, the proportion of patients with severe co-
morbidities and advanced age is rising and thus surgical
risk may be deemed prohibitively high. For these patients,
TAVI has become an alternative treatment option, and cen-
ters throughout Europe have rapidly adopted this new inter-
ventional technique.
After market approval, European centers have rapidly
adopted the metallic stented TAVI devices (Edwards SA-
PIEN and Medtronic CoreValve). Data from ongoing regis-
tries of both devices reveal mortality rates of less than 10%
in experienced centers.6-8 For both valve types, second- or902 The Journal of Thoracic and Cardiovascular Surgthird-generation devices are now available and have over-
come the developmental stage of a first-in-man device.
As a favorable advantage over metallic stented valves, the
Direct Flow Medical aortic valve offers the possibility of
valve repositioning and valve retrieval during the procedure.
Nevertheless, the device used in this study is a first-
generation device and the data reported in this study reflect
the first-in-man experience with this novel valve type.
Therefore, procedural results should be compared with the
first-generation results of the SAPIEN and CoreValve
devices.
In 2006 Grube and associates9 reported on the first-in-man
experience of the percutaneous implantation of the Core-
Valve prosthesis in 25 patients with a median logistic Euro-
SCORE of only 11.0%. Device success and procedural
success were achieved in 22 (88%) and 21 (84%) patients,
respectively. Mortality was 20% (5/25 patients) before dis-
charge and the MACCE rate was 32% (8/25 patients).
In 2007 Webb and colleagues10 reported on the early
experience with the Edwards SAPIEN prosthesis. Transfe-
moral valve implantation was attempted in 50 patients
(EuroSCORE 28%) with a procedural success rate of
86% (76% in the first 25 patients and 96% in the last 25 pa-
tients). Thirty-day mortality was 12% (6/50 patients), and
procedure-related strokes occurred in 2 patients.
When compared with those results, the procedural success
rate of the novel Direct Flow Medical aortic valve was lower
(71%, 22/31 patients). This is possibly due to the lack of ex-
perience with transcatheter heart valve techniques during the
initial stage of the study, as the Direct Flow Medical aortic
valve is the first type of transcatheter aortic valve used at
the University Heart Center, Hamburg. With current experi-
ence of more than 1000 TAVI cases at our center, a more re-
fined patient selection process may have had a more positive
impact on patient outcomes.
Nevertheless, the 30-day mortality rate of 12.9% (4/31 pa-
tients) compares favorably with data from first-in-man series
of both CoreValve and Edwards SAPIEN prostheses.9,10
Preoperative risk assessment revealed a mean logistic
EuroSCORE of 28%  7% resulting from advanced age
and relevant comorbidities in this high-risk patient population.
In addition, the rate of cerebrovascular complications has
been very low with only one periprocedural stroke. Presum-
ably, this is due to the high degree of flexibility of the deliv-
ery system and the olive-shaped tip facilitating a safe and
atraumatic passage across the aortic arch and the native
valve, even in patients with complex aortic calcifications.
An additional device-specific advantage of the Direct
Flow Medical valve is its entirely subcoronary position,
minimizing the risk of coronary ostial obstruction and com-
promised coronary perfusion.
In this stentless valve type, the number of balloon valvu-
loplasties and, accordingly, the number of rapid pacing epi-
sodes needed to create an adequate circular opening in theery c October 2010




Snative annulus was higher than in metallic framed valve
types. The importance of a circular opening is emphasized
by 1 particular case in which a noncircular distortion of
the upper ring resulted in an increased gradient that led to
surgical aortic valve replacement 2 days after the procedure.
A possible reason for the failure could be the lower radial
force of this valve design as compared with stent-based
valve types. Furthermore, in 2 patients valve implantation
failed because of functionally bicuspid valves that did not re-
spond sufficiently to balloon valvuloplasty even after multi-
ple inflations. Bicuspid valves are now contraindicated for
both of the commercially available metallic stented valves
as well.
On the other hand, ventricular pacing is not necessary dur-
ing the positioning process, allowing for controlled position-
ing, deployment, and even repositioning of the prosthesis
under constant TEE monitoring on the beating heart. This
stands in contrast to single-shot devices like the CoreValve
and Edwards SAPIEN valves, which have only very limited
options to correct malpositioning once the valve has been
deployed.
Another important advantage of a nonmetallic valve
design is that it effectively reduces paravalvular leakage.
The majority of patients followed up to date do not show sig-
nificant paravalvular or central leakages at 6 months. This
compares favorably with published rates even of the latest
generation of stent-based metallic valves.9-12
In contrast to commercially available stent-based metallic
valves; the Direct Flow Medical aortic valve is reposition-
able and retrievable. In those patients in whom the implant
could not be optimally positioned (n ¼ 5), retrieval of the
valve was safe. In patients in whom prosthesis size was mis-
calculated, the initial valve was easily retrieved and replaced
by a properly sized implant. Therefore, retrieval complica-
tions owing to incorrect sizing or positioning of the valve
did not occur.
In this safety and feasibility trial of the Direct Flow Med-
ical aortic valve, the number of patients who could not be
treated successfully demonstrates the need for proper patient
selection and expresses the impact of the learning curve with
this new technique. Patients with excessive calcification of
the aortic valve or of the left ventricular outflow tract were
unsuitable candidates for the implantation of a nonmetallic
stentless valve prosthesis. Patients with moderate calcifica-The Journal of Thoracic and Cations may profit from the flexible design of the valve and
the delivery system with regard to a lower rate of paravalv-
ular leaks, a low stroke rate, and the possibility for valve
repositioning and retrieval.
The results of this study cannot be transferred to patients
of younger age and nonsignificant surgical risk profiles.
Long-term results of this valve beyond 6 months must be ob-
served before final statements about longevity and perfor-
mance can be made. Increased patient experience and
a careful patient selection process will help to define reliable
morbidity and mortality rates for this novel device.References
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